ATE286130T1 - Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten - Google Patents

Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten

Info

Publication number
ATE286130T1
ATE286130T1 AT99912001T AT99912001T ATE286130T1 AT E286130 T1 ATE286130 T1 AT E286130T1 AT 99912001 T AT99912001 T AT 99912001T AT 99912001 T AT99912001 T AT 99912001T AT E286130 T1 ATE286130 T1 AT E286130T1
Authority
AT
Austria
Prior art keywords
vaccines
genes
mucin binding
aggregation
pathogenic
Prior art date
Application number
AT99912001T
Other languages
English (en)
Inventor
Ivan Casas
Hans Jonsson
Bo Mollstam
Stefan Roos
Original Assignee
Biogaia Biolog Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Biolog Ab filed Critical Biogaia Biolog Ab
Application granted granted Critical
Publication of ATE286130T1 publication Critical patent/ATE286130T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT99912001T 1998-03-16 1999-03-16 Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten ATE286130T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/039,773 US6100388A (en) 1998-03-16 1998-03-16 Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
PCT/IB1999/000705 WO1999047657A2 (en) 1998-03-16 1999-03-16 Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles

Publications (1)

Publication Number Publication Date
ATE286130T1 true ATE286130T1 (de) 2005-01-15

Family

ID=21907276

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912001T ATE286130T1 (de) 1998-03-16 1999-03-16 Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten

Country Status (8)

Country Link
US (1) US6100388A (de)
EP (1) EP1066375B1 (de)
AT (1) ATE286130T1 (de)
AU (1) AU767143B2 (de)
CA (1) CA2323634A1 (de)
DE (1) DE69922937T2 (de)
ES (1) ES2237094T3 (de)
WO (1) WO1999047657A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
FR2778187B1 (fr) * 1998-04-30 2001-06-22 Sanofi Elf Procede de selection de souches bacteriennes
US6146411A (en) * 1998-12-24 2000-11-14 Alsius Corporation Cooling system for indwelling heat exchange catheter
EP1246848A1 (de) * 1999-12-27 2002-10-09 University Of Manitoba Genetische impfstoffe zur herstellung von antikörpern aus dem eigelb von hühnern gegen enterotoxigenes escherichia coli und sonstige pathogenen
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
US7498162B2 (en) * 2000-09-25 2009-03-03 Nestec S.A. Lactic acid bacteria capable of reducing an individual's tendency to develop allergic reactions
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
DE60227498D1 (de) * 2001-03-23 2008-08-21 Advanced Bionutrition Corp Abgabe von mitteln zur krankheitskontrolle in aquakultur unter verwendung von bioaktive proteine enthaltender hefe
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
DK1478659T3 (da) 2001-07-13 2009-01-05 Cms Peptides Patent Holding Co Biologisk aktive peptider
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
US6872565B2 (en) * 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050220777A1 (en) * 2003-11-21 2005-10-06 Stefan Roos Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
TWI353252B (en) 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1723965A1 (de) * 2005-05-18 2006-11-22 Stallergenes Sa Zusammensetzungen zur Einleitung antigenspezifischer immunologischer Toleranz durch orale Immunisierung
WO2007015918A2 (en) 2005-07-26 2007-02-08 Cms Peptides Patent Holding Company Limited Novel biologically active peptides and their new uses
EP2119450B1 (de) 2005-11-29 2013-02-13 Actogenix N.V. Induktion von mukosaler Toleranz für pankreatische Beta-Inselzell-Autoantigene
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US20110184387A1 (en) * 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20080260898A1 (en) * 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
US7374924B2 (en) 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
DK2774621T3 (en) 2007-01-25 2018-05-07 Intrexon Actobiotics Nv TREATMENT OF IMMUNE DISEASE BY MUCOSAL ADMINISTRATION OF ANTIGENS
US7910127B2 (en) * 2007-03-02 2011-03-22 Biogaia Ab Use of lactic acid bacteria for improving food lysine absorption of pet animals
EP2164512A2 (de) * 2007-06-20 2010-03-24 Actogenix N.V. Verfahren und zusammensetzungen zur behandlung von mucositis
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
EP2897638A1 (de) 2012-09-24 2015-07-29 Montana State University-Bozeman Rekombinanter lactococcus lactis zur expression des escherichia coli-kolonisationsfaktor-antigens i (cfa/i) fimbriae und verfahren zu deren verwendung
EP2956169B1 (de) 2013-02-12 2018-04-11 THE UNITED STATES OF AMERICA, represented by the S Monoklonale antikörper zur neutralisierung von noroviren
WO2014183052A1 (en) 2013-05-09 2014-11-13 The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use
MX2016012597A (es) 2014-03-27 2017-04-27 Sambuddha Ghosh Expresion de un anticuerpo de cadena sencilla contra la salmonella en lactobacillus.
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
US10808014B2 (en) * 2016-09-13 2020-10-20 Intrexon Actobiotics N.V. Mucoadhesive microorganism
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
CN107961373A (zh) * 2017-11-14 2018-04-27 东北农业大学 一种用于预防猪流行性腹泻的基因工程亚单位口服疫苗株及其构建方法和用途
BR112021015289A2 (pt) * 2019-02-05 2021-10-05 Elanco Us Inc. Composição, método para melhorar saúde animal, e, método para tratar, melhorar os efeitos ou prevenir a enterite necrótica em aves
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2023078279A1 (zh) * 2021-11-04 2023-05-11 澄交生物科技股份有限公司 免疫原性组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
SE9302856D0 (sv) * 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing a plasmapeotein-binding protein
WO1996032486A1 (en) * 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle

Also Published As

Publication number Publication date
AU3049699A (en) 1999-10-11
EP1066375B1 (de) 2004-12-29
AU767143B2 (en) 2003-10-30
US6100388A (en) 2000-08-08
EP1066375A2 (de) 2001-01-10
DE69922937D1 (de) 2005-02-03
ES2237094T3 (es) 2005-07-16
CA2323634A1 (en) 1999-09-23
WO1999047657A2 (en) 1999-09-23
DE69922937T2 (de) 2005-12-29
WO1999047657A3 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
ATE286130T1 (de) Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten
Jimenez et al. Microbial therapeutics: new opportunities for drug delivery
EP1458856B1 (de) Isolierte phagen und ihre verwendung in lebensmittel- und haustierfutterprodukten
Frece et al. Importance of S‐layer proteins in probiotic activity of Lactobacillus acidophilus M92
Mohamadzadeh et al. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
Pascual et al. Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response
JP2005529960A5 (de)
Iyer et al. Release studies of Lactobacillus casei strain Shirota from chitosan‐coated alginate‐starch microcapsules in ex vivo porcine gastrointestinal contents
CN108728473A (zh) 一种表达幽门螺杆菌NapA蛋白的重组载体、重组菌株及其制备方法、应用
Karem et al. Differential induction of carrier antigen-specific immunity by Salmonella typhimurium live-vaccine strains after single mucosal or intravenous immunization of BALB/c mice
Ogawa et al. Oral immunoadjuvant activity of a new synbiotic Lactobacillus casei subsp casei in conjunction with dextran in BALB/c mice
JP2018505666A5 (de)
Douraghi et al. Comparative evaluation of three supplements for Helicobacter pylori growth in liquid culture
Plant et al. Adjuvant properties and colonization potential of adhering and non-adhering Lactobacillus spp. following oral administration to mice
Howard A prototype live oral cholera vaccine
JP7358002B2 (ja) バチルス属細菌、インターロイキン－２２産生誘導剤、皮膚バリア機能増強剤
RU2441907C1 (ru) Способ приготовления лечебно-профилактического препарата из живых штаммов микроорганизмов лакто- и бифидобактерий "lb-комплекс л"
Shonyela et al. Recombinant Lactobacillus plantarum NC8 strain expressing porcine rotavirus VP7 induces specific antibodies in BALB/c mice
Zhang et al. Auxotrophic Lactobacillus expressing porcine rotavirus VP4 constructed using CRISPR-Cas9D10A system induces effective immunity in mice
CN104232502A (zh) 维罗纳气单胞菌菌蜕、其制备方法及应用
Rosales-Mendoza et al. Nanovaccines and the History of Vaccinology
Bagadi Production and counting of spores of Clostridium chauvoei
Abdel-Megeed Therapeutic impact of probiotics in various aspects: a novel prospective strategy
CN103421731A (zh) 一种副猪嗜血杆菌减毒沙门氏菌苗

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066375

Country of ref document: EP

REN Ceased due to non-payment of the annual fee